Tolerogenic dendritic cells immunotherapy protects against IgA nephropathy

Area of Science:

• Immunology
• Nephrology
• Cell Therapy

Background:

• IgA nephropathy (IgAN) is a chronic kidney disease characterized by IgA deposition in the glomeruli.
• Current treatments for IgAN are limited, highlighting the need for novel therapeutic strategies.
• Tolerogenic dendritic cells (tolDCs) possess immunosuppressive properties and have emerged as a potential cell-based therapy.

Purpose of the Study:

• To investigate the therapeutic efficacy of IL-10-induced tolerogenic dendritic cells (tolDCs) in a mouse model of IgA nephropathy (IgAN).
• To assess the impact of tolDCs on renal pathology, immune cell infiltration, and inflammatory cytokine profiles in IgAN mice.

Main Methods:

• An IgAN mouse model was established using oral mucosal immunization.
• Bone marrow-derived dendritic cells (BMDCs) were differentiated into tolDCs using IL-10, characterized by PD-L1 and IL-10 expression.
• IgAN mice received either PBS or tolDCs, followed by analysis of renal function, histology, and cytokine levels.

Main Results:

• IL-10-induced tolDCs demonstrated an immunosuppressive phenotype with increased PD-L1 and IL-10 expression.
• Treated IgAN mice showed significant reductions in glomerular and tubulointerstitial IgA deposition (59.3% and 55.4%, respectively).
• tolDCs therapy promoted regulatory T cell (Treg) accumulation in the kidneys and suppressed pro-inflammatory cytokines (IL-12, TGF-β) while upregulating IL-10.

Conclusions:

• IL-10-induced tolDCs are effective in attenuating renal immunoinflammatory injury in IgAN mice.
• The therapy alleviates IgA deposition, enhances Treg infiltration, and modulates cytokine profiles, indicating safety and efficacy.
• Tolerogenic dendritic cells represent a promising targeted immunotherapy for IgA nephropathy.